TSS
TLIS

Two Sigma Securities’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Two Sigma Securities’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,267
Closed -$23.5K – 3606
2023
Q2 		$23.5K Buy
+3,267
New +$23.7K ﹤0.01% 2484

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Two Sigma Securities's TLIS Position: Q3 2023 in Review

Two Sigma Securities sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2023, closing a stake of 3,267 shares — an estimated $23.5K sold.

Two Sigma Securities first reported a position in TLIS in Q2 2023 and held it in 1 quarter. The position peaked at $23.5K in Q2 2023. 19 funds tracked by Wall St. Rank hold TLIS as of Q3 2023.

  • Two Sigma Securities reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Securities sold 3,267 Talis Biomedical Corporation Common Stock shares in Q3 2023, an estimated $23.5K.
  • Two Sigma Securities first reported a position in Talis Biomedical Corporation Common Stock in Q2 2023 and held it in 1 quarter.
  • Two Sigma Securities's Talis Biomedical Corporation Common Stock position peaked at $23.5K in Q2 2023.
  • 19 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2023.

Based on Two Sigma Securities's 13F filing for Q3 2023, filed 14 Nov 2023.